Covid-19 Impact on Point of Care Testing for Infectious Disease Market, Global Research Reports 2020-2021

2 Global Point of Care Testing for Infectious Disease Quarterly Market Size Analysis

• 2.1 Point of Care Testing for Infectious Disease Business Impact Assessment - COVID-19
  • 2.1.1 Global Point of Care Testing for Infectious Disease Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Point of Care Testing for Infectious Disease Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Point of Care Testing for Infectious Disease Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Point of Care Testing for Infectious Disease Headquarters and Area Served
• 3.3 Date of Key Players Enter into Point of Care Testing for Infectious Disease Market
• 3.4 Key Players Point of Care Testing for Infectious Disease Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Point of Care Testing for Infectious Disease Segments, By Type

• 4.1 Introduction
  • 1.4.1 Immunological Test
  • 1.4.2 Pathogen Nucleic Acid Test
• 4.2 By Type, Global Point of Care Testing for Infectious Disease Market Size, 2019-2021

5 Impact of Covid-19 on Point of Care Testing for Infectious Disease Segments, By Application

• 5.1 Overview
  • 5.5.1 Hospital
  • 5.5.2 Clinics
  • 5.5.3 Others
• 5.2 By Application, Global Point of Care Testing for Infectious Disease Market Size, 2019-2021
  • 5.2.1 By Application, Global Point of Care Testing for Infectious Disease Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Abbott
  • 7.1.1 Abbott Business Overview
  • 7.1.2 Abbott Point of Care Testing for Infectious Disease Quarterly Revenue, 2020
  • 7.1.3 Abbott Point of Care Testing for Infectious Disease Product Introduction
  • 7.1.4 Abbott Response to COVID-19 and Related Developments
• 7.2 Roche
  • 7.2.1 Roche Business Overview
  • 7.2.2 Roche Point of Care Testing for Infectious Disease Quarterly Revenue, 2020
  • 7.2.3 Roche Point of Care Testing for Infectious Disease Product Introduction
  • 7.2.4 Roche Response to COVID-19 and Related Developments
• 7.3 Siemens
  • 7.3.1 Siemens Business Overview
  • 7.3.2 Siemens Point of Care Testing for Infectious Disease Quarterly Revenue, 2020
  • 7.3.3 Siemens Point of Care Testing for Infectious Disease Product Introduction
  • 7.3.4 Siemens Response to COVID-19 and Related Developments
• 7.4 Danaher
  • 7.4.1 Danaher Business Overview
  • 7.4.2 Danaher Point of Care Testing for Infectious Disease Quarterly Revenue, 2020
  • 7.4.3 Danaher Point of Care Testing for Infectious Disease Product Introduction
  • 7.4.4 Danaher Response to COVID-19 and Related Developments
• 7.5 Becton, Dickinson
  • 7.5.1 Becton, Dickinson Business Overview
  • 7.5.2 Becton, Dickinson Point of Care Testing for Infectious Disease Quarterly Revenue, 2020
  • 7.5.3 Becton, Dickinson Point of Care Testing for Infectious Disease Product Introduction
  • 7.5.4 Becton, Dickinson Response to COVID-19 and Related Developments
• 7.6 Johnson & Johnson
  • 7.6.1 Johnson & Johnson Business Overview
  • 7.6.2 Johnson & Johnson Point of Care Testing for Infectious Disease Quarterly Revenue, 2020
  • 7.6.3 Johnson & Johnson Point of Care Testing for Infectious Disease Product Introduction
  • 7.6.4 Johnson & Johnson Response to COVID-19 and Related Developments
• 7.7 Instrumentation Laboratory
  • 7.7.1 Instrumentation Laboratory Business Overview
  • 7.7.2 Instrumentation Laboratory Point of Care Testing for Infectious Disease Quarterly Revenue, 2020
  • 7.7.3 Instrumentation Laboratory Point of Care Testing for Infectious Disease Product Introduction
  • 7.7.4 Instrumentation Laboratory Response to COVID-19 and Related Developments
• 7.8 PTS Diagnostics
  • 7.8.1 PTS Diagnostics Business Overview
  • 7.8.2 PTS Diagnostics Point of Care Testing for Infectious Disease Quarterly Revenue, 2020
  • 7.8.3 PTS Diagnostics Point of Care Testing for Infectious Disease Product Introduction
  • 7.8.4 PTS Diagnostics Response to COVID-19 and Related Developments
• 7.9 Quidel
  • 7.9.1 Quidel Business Overview
  • 7.9.2 Quidel Point of Care Testing for Infectious Disease Quarterly Revenue, 2020
  • 7.9.3 Quidel Point of Care Testing for Infectious Disease Product Introduction
  • 7.9.4 Quidel Response to COVID-19 and Related Developments
• 7.10 Sekisui Diagnostics
  • 7.10.1 Sekisui Diagnostics Business Overview
  • 7.10.2 Sekisui Diagnostics Point of Care Testing for Infectious Disease Quarterly Revenue, 2020
  • 7.10.3 Sekisui Diagnostics Point of Care Testing for Infectious Disease Product Introduction
  • 7.10.4 Sekisui Diagnostics Response to COVID-19 and Related Developments
• 7.11 Nova
  • 7.11.1 Nova Business Overview
  • 7.11.2 Nova Point of Care Testing for Infectious Disease Quarterly Revenue, 2020
  • 7.11.3 Nova Point of Care Testing for Infectious Disease Product Introduction
  • 7.11.4 Nova Response to COVID-19 and Related Developments
• 7.12 EKF Diagnostics
  • 7.12.1 EKF Diagnostics Business Overview
  • 7.12.2 EKF Diagnostics Point of Care Testing for Infectious Disease Quarterly Revenue, 2020
  • 7.12.3 EKF Diagnostics Point of Care Testing for Infectious Disease Product Introduction
  • 7.12.4 EKF Diagnostics Response to COVID-19 and Related Developments
• 7.13 AccuBioTech
  • 7.13.1 AccuBioTech Business Overview
  • 7.13.2 AccuBioTech Point of Care Testing for Infectious Disease Quarterly Revenue, 2020
  • 7.13.3 AccuBioTech Point of Care Testing for Infectious Disease Product Introduction
  • 7.13.4 AccuBioTech Response to COVID-19 and Related Developments
• 7.14 Trinity Biotech
  • 7.14.1 Trinity Biotech Business Overview
  • 7.14.2 Trinity Biotech Point of Care Testing for Infectious Disease Quarterly Revenue, 2020
  • 7.14.3 Trinity Biotech Point of Care Testing for Infectious Disease Product Introduction
  • 7.14.4 Trinity Biotech Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US